Gary P Cook

US Patent:

20050260153, Nov 24, 2005

Filed:

Apr 13, 2005

Appl. No.:

11/104812

Inventors:

Pericles Calias - Melrose MA, US
Gary Cook - Westford MA, US
David Shima - Boston MA, US
David Turner - Norwell MA, US
Mary Ganley - Norwood MA, US

International Classification:

A61K031/785
A61K031/716

US Classification:

424078270, 514054000, 514057000, 514055000

Abstract:

The invention provides compositions and methods for making and using sterically enhanced antagonist aptamer conjugates that include a nucleic acid sequence having a specific affinity for a target molecule and a soluble, high molecular weight steric group that augments or facilitates the inhibition of binding to, or interaction with, the target molecule binding partner by the target molecule when bound to the aptamer conjugate. The present invention also provides methods and formulations for ocular delivery of a biologically active molecule by attaching a charged moiety to the biologically active molecule and delivering the biologically active molecule by iontophoresis. Iontophoresis of a biologically active molecule that is conjugated to a high molecular weight neutral moiety, in enhanced by substituting the high molecular weight neutral moiety with a charged molecule of comparable size.

US Patent:

20050260651, Nov 24, 2005

Filed:

Apr 13, 2005

Appl. No.:

11/105279

Inventors:

Pericles Calias - Melrose MA, US
Gary Cook - Westford MA, US
David Shima - Boston MA, US
Anthony Adamis - Boston MA, US
Yin-Shan Ng - North Billerica MA, US
Gregory Robinson - Wilmington MA, US
David Turner - Norwell MA, US
Mary Ganley - Norwood MA, US

International Classification:

C12Q001/68
C08G063/48

US Classification:

435006000, 525054200

Abstract:

The invention provides compositions and methods for making and using sterically enhanced antagonist aptamer conjugates that include a nucleic acid sequence having a specific affinity for a target molecule and a soluble, high molecular weight steric group that augments or facilitates the inhibition of binding to, or interaction with, the target molecule binding partner by the target molecule when bound to the aptamer conjugate. The present invention also provides methods and formulations for ocular delivery of a biologically active molecule by attaching a charged moiety to the biologically active molecule and delivering the biologically active molecule by iontophoresis. Iontophoresis of a biologically active molecule that is conjugated to a high molecular weight neutral moiety, in enhanced by substituting the high molecular weight neutral moiety with a charged molecule of comparable size.

US Patent:

52513017, Oct 5, 1993

Filed:

May 22, 1992

Appl. No.:

7/888043

Inventors:

Gary M. Cook - Pepperell MA

Assignee:

PC Connection, Inc. - Marlow NH

International Classification:

G06F 1516
H04N 708

US Classification:

395200

Abstract:

A system for simultaneously using a video signal to provide a video picture and computer data. At the transmitting end, a video signal is digitized and then modified by substituting digital signals representative of computer data for those representative of video pixels. The modified signal is reconverted to an analog signal and transmitted to a receiver. The receiver displays the video picture corresponding to the modified signal and extracts the computer data so that they may be provided to the computer. The computer can thus be controlled by the computer data as the video picture is being displayed.

US Patent:

49205030, Apr 24, 1990

Filed:

May 27, 1988

Appl. No.:

7/199624

Inventors:

Gary M. Cook - Pepperell MA

Assignee:

PC Connection, Inc. - Marlow NH

International Classification:

G06F 300
H04N 708

US Classification:

364521

Abstract:

A system for simultaneously using a video signal to provide a video picture and computer data. At the transmitting end, a video signal is digitized and then modified by substituting digital signals representative of computer data for those representative of video pixels. The modified signal is reconverted to an analog signal and transmitted to a receiver. The receiver displays the video picture corresponding to the modified signal and extracts the computer data so that they may be provided to the computer. The computer can thus be controlled by the computer data as the video picture is being displayed.

US Patent:

20200345647, Nov 5, 2020

Filed:

Nov 28, 2018

Appl. No.:

16/767803

Inventors:

- Wiltshire, GB
Gary Paul COOK - Westford MA, US
Jamie Joseph FARRAR - Flintshire, GB
Michael John FRODSHAM - Flintshire, GB
Michael Bryan ROE - Wiltshire, GB
Richard Simon TODD - Wiltshire, GB
Robert Neil WARD - Flintshire, GB

International Classification:

A61K 9/48
C07D 401/14
A61K 9/16
A61K 9/20
A61K 9/28

Abstract:

The present invention relates to oral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compound of Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of Formula A using Form 1 of the compound of Formula A.

US Patent:

20160263024, Sep 15, 2016

Filed:

Mar 10, 2016

Appl. No.:

15/066689

Inventors:

- Waltham MA, US
Gary Cook - Westford MA, US
Perry Calias - Melrose MA, US
Michael A. Patane - Waltham MA, US

International Classification:

A61K 9/00
A61N 1/30
A61K 31/573

Abstract:

Disclosed herein are formulations of dexamethasone or a prodrug thereof suitable for delivery by ocular iontophoresis and methods of use thereof.

US Patent:

20150037429, Feb 5, 2015

Filed:

Sep 18, 2014

Appl. No.:

14/489863

Inventors:

- Bridgewater NJ, US
Pericles Calias - Melrose MA, US
Gary P. Cook - Westford MA, US
Mary A. Ganley - Norwood MA, US

International Classification:

A61K 38/18
A61K 9/00

US Classification:

424501, 514 44 R

Abstract:

Formulations for controlled, sustained release of biologically active agents for the treatment of ocular disorders have been developed. These formulations are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof. The microparticles are characterized by low burst levels and efficient drug loading and sustained release.